Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 6/20 | 0.52 |
| ▸ | PI4K2B | Q8TCG2 | 6/20 | 0.52 |
| ▸ | PI4K2A | Q9BTU6 | 6/20 | 0.52 |
| ▸ | PI4KB | Q9UBF8 | 6/20 | 0.52 |
| ▸ | LIMK1 | P53667 | 3/20 | 0.47 |
| ▸ | CLK1 | P49759 | 2/20 | 0.47 |
| ▸ | CDC7 | O00311 | 1/20 | 0.47 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.42 |
| ▸ | NOS3 | P29474 | 2/20 | 0.42 |
| ▸ | NOS1 | P29475 | 2/20 | 0.42 |
| ▸ | NOS2 | P35228 | 2/20 | 0.42 |
| ▸ | F12 | P00748 | 1/20 | 0.42 |
| ▸ | PLAU | P00749 | 1/20 | 0.42 |
| ▸ | NCF1 | P14598 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | RET | P07949 | 2/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2041433 | 1.00 | PI4KA (0.52) | PI4KAPI4K2BPI4K2API4KBLIMK1 | |
| SCHEMBL29427603 | 1.00 | PI4KA (0.52) | PI4KAPI4K2BPI4K2API4KBLIMK1 | |
| SCHEMBL30092842 | 0.86 | PI4KA (0.41) | PI4KAPI4K2BPI4K2API4KBLIMK1 | |
| SCHEMBL12559949 | 0.74 | EGFR (0.41) | LIMK1CLK1CDC7DBF4EGFR | |
| SCHEMBL31662896 | 0.74 | L3MBTL1 (0.45) | NOS3NOS1NOS2BACE1EGFR | |
| SCHEMBL30880053 | 0.74 | EGFR (0.41) | EGFRMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL6837820 | 0.74 | EGFR (0.41) | LIMK1CLK1CDC7DBF4EGFR | |
| SCHEMBL2210491 | 0.74 | EGFR (0.41) | EGFRMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL1065478 | 0.74 | PDE4A (0.52) | CDC7MAP4K4EGFRMEN1KMT2A | |
| SCHEMBL29416394 | 0.74 | PDE4A (0.52) | CDC7MAP4K4EGFRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3802495-B1 | 4-(2-((2-CHLOROQUINOLIN-4-YL)AMINO)ETHYL)BENZENESULFONAMIDE DERIVATIVES AS STAT3 INHIBITORS FOR THE TREATMENT OF CANCER | C&C RES LAB (KR) | 2025-07-02 | — | — | EP | claimed |
| US-11518760-B2 | Anti-Wolbachia pyrido[2,3-d]pyrimidine compounds | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2022-12-06 | — | — | US | claimed |
| CN-114222741-A | As P2X3Suppression ofPyridopyrimidine derivatives as agents | 奇斯药制品公司 | 2022-03-22 | — | — | CN | claimed |
| US-12606562-B2 | Pyridopyrimidines derivatives as P2X3 inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2026-04-21 | — | — | US | disclosed |
| US-12545675-B2 | Anti-wolbachia pyrido[2,3-d]pyrimidine compounds | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2026-02-10 | — | — | US | disclosed |
| WO-2025202022-A1 | ANTICANCER MACROCYCLIC QUINAZOLINE-BASED INHIBITORS OF THE INERACTION BETWEEN RAS AND SOS1 | BAYER AKTIENGESELLSCHAFT (DE) | 2025-10-02 | — | — | WO | disclosed |
| CN-116323623-B | Pyrido [2,3-d ] pyrimidin-4-amines as SOS1 inhibitors | 拜耳公司 | 2025-09-26 | — | — | CN | disclosed |
| EP-4466270-A1 | FUSED HETEROCYCLIC COMPOUNDS AS MODULATORS OF RAS SIGNALLING | Shenzhen Ionova Life Science Co., Ltd. (CN) | 2024-11-27 | — | — | EP | disclosed |
| US-20240254117-A1 | PYRIMIDO-HETEROCYCLIC COMPOUNDS, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI RINGENE BIOPHARMA CO., LTD. (CN) | 2024-08-01 | — | — | US | disclosed |
| CN-114685487-B | Pyrimidine heterocyclic compounds, preparation method and application | 上海凌达生物医药有限公司 | 2024-04-19 | — | — | CN | disclosed |
| EP-4346806-A2 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | Biocryst Pharmaceuticals, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| CN-115536660-A | Benzylamino-substituted heteropolycyclic compounds, compositions, formulations and uses thereof | 北京福元医药股份有限公司 | 2022-12-30 | — | — | CN | disclosed |
| US-11518760-B2 | Anti-Wolbachia pyrido[2,3-d]pyrimidine compounds | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2022-12-06 | — | — | US | disclosed |
| WO-2022251188-A2 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | BIOCRYST PHARMACEUTICALS, INC. (US) | 2022-12-01 | — | — | WO | disclosed |
| CN-113801114-B | Fused bicyclic heteroaryl derivative, preparation method and application thereof in medicines | 江苏恒瑞医药股份有限公司 | 2022-11-18 | — | — | CN | disclosed |
| WO-2022161461-A1 | SOS1 INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 江苏先声药业有限公司 | 2022-08-04 | — | — | WO | disclosed |
| US-20220235060-A1 | PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARM SPA (IT) | 2022-07-28 | — | — | US | disclosed |
| WO-2022156792-A1 | HETEROCYCLIC COMPOUNDS AS SOS1 INHIBITORS | GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) | 2022-07-28 | — | — | WO | disclosed |
| CN-114539245-A | Pyrimidine-fused ring derivative-containing regulator, and preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-114222741-A | As P2X3Suppression ofPyridopyrimidine derivatives as agents | 奇斯药制品公司 | 2022-03-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545675-B2 | Anti-wolbachia pyrido[2,3-d]pyrimidine compounds | CBR1, CBR3, COX6C | PI4KA 3988/4885PI4K2B 3435/4885PI4K2A 4027/4885 |
| US-20220235060-A1 | PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS | P2RX3, P2RX5, P2RX1 | PI4KA 662/4885PI4K2B 926/4885PI4K2A 1014/4885 |
| US-12606562-B2 | Pyridopyrimidines derivatives as P2X3 inhibitors | P2RX3, P2RX1, P2RX2 | PI4KA 971/4885PI4K2B 973/4885PI4K2A 1132/4885 |
| US-20240254117-A1 | PYRIMIDO-HETEROCYCLIC COMPOUNDS, AND PREPARATION METHOD THEREFOR AND USE THEREOF | TYMS, TYMP, SLC5A11 | PI4KA 1531/4885PI4K2B 1733/4885PI4K2A 1967/4885 |
| US-11518760-B2 | Anti-Wolbachia pyrido[2,3-d]pyrimidine compounds | P2RX5, PNPO, P2RX3 | PI4KA 2418/4885PI4K2B 2156/4885PI4K2A 2520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.